| Description | GPR110 peptide agonist P12 acetate is the acetate salt form of GPR110 peptide agonist P12 (HY-P10495). GPR110 peptide agonist P12 acetateis a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 acetate can significantly enhance the initial rate of GPR110 stimulated G protein GTPγSGPR110 peptide agonist P12 acetate is the acetate salt form of GPR110 peptide agonist P12 (HY-P10495). GPR110 peptide agonist P12 acetateis a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 acetate can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 acetate mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 acetate can be used in the study of developmental disorders and cancers related to GPR110[1]... Read More | BAM(8-22), a proteolytically cleaved product of proenkephalin A, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1, and induces scratching in mice in an Mrgpr-dependent manner[1] | Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosisBulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2]... Read More | Chymostatin is a SARS-CoV-2 Mpro inhibitor. Chymostatin up-regulates endocan and inhibits NF-κBp65 activity. Chymostatin reduces proinflammatory cytokines (IL-1β and IL-6) and HMGB1. Chymostatin shows protective effects against Paraquat-induced acute lung injury. Chymostatin exhibits Chymostatin is a SARS-CoV-2 Mpro inhibitor. Chymostatin up-regulates endocan and inhibits NF-κBp65 activity. Chymostatin reduces proinflammatory cytokines (IL-1β and IL-6) and HMGB1. Chymostatin shows protective effects against Paraquat-induced acute lung injury. Chymostatin exhibits anticancer activity against lung cancer[1][2][3][4][5][6][7]... Read More | DAMGO is a µ-opioid receptor (µ-OPR ) selective agonist with a Kd of 3.46 nM for native µ-OPR[1] |